Ziconotide

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Ziconotide
Accession Number
DB06283
Type
Small Molecule
Groups
Approved
Description

Ziconotide (SNX-111; Prialt) is an atypical analgesic agent used in severe and chronic pain. It is a synthetic form of ω-conotoxin, a peptide toxin derived from Conus magus (Cone Snail). It was approved as an intrathecal formulation by the FDA in December 2004.

Synonyms
  • Ziconotida
  • Ziconotide
External IDs
SNX-111
Product Ingredients
IngredientUNIICASInChI Key
Ziconotide acetateT2I226K69M914454-03-8Not applicable
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PrialtInjection, solution25 μg/mlIntrathecalEisai Limited2005-02-21Not applicableEu
PrialtInjection, solution100 ug/1mLIntrathecalTersera Therapeutics Llc2018-10-15Not applicableUs
PrialtInjection, solution100 ug/1mLIntrathecalJazz Pharmaceuticals, Inc.2004-12-282022-08-31Us
PrialtInjection, solution100 μg/mlIntrathecalEisai Limited2005-02-21Not applicableEu
PrialtInjection, solution25 ug/1mLIntrathecalTersera Therapeutics Llc2018-10-15Not applicableUs
PrialtInjection, solution100 ug/1mLIntrathecalJazz Pharmaceuticals, Inc.2004-12-282022-09-30Us
PrialtInjection, solution100 μg/mlIntrathecalEisai Limited2005-02-21Not applicableEu
PrialtInjection, solution100 ug/1mLIntrathecalElan Pharmaceuticals2004-12-282013-04-01Us
PrialtInjection, solution100 ug/1mLIntrathecalElan Pharmaceuticals, Inc.2007-05-072007-05-07Us
PrialtInjection, solution25 ug/1mLIntrathecalJazz Pharmaceuticals, Inc.2004-12-282022-07-31Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
7I64C51O16
CAS number
107452-89-1
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action

Ziconotide acts as a selective N-type voltage-gated calcium channel blocker, inhibiting the release of pro-nociceptive neurochemicals like glutamate, calcitonin gene-related peptide (CGRP), and substance P in the brain and spinal cord by blocking calcium entry into axons. The reduction in these nociceptive mediators leads to improved pain control.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be decreased when combined with Ziconotide.
(S)-WarfarinThe metabolism of (S)-Warfarin can be decreased when combined with Ziconotide.
2,4-thiazolidinedioneThe risk or severity of hypoglycemia can be increased when Ziconotide is combined with 2,4-thiazolidinedione.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Ziconotide is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Ziconotide.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Ziconotide.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Ziconotide.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Ziconotide.
5-androstenedioneThe metabolism of Ziconotide can be decreased when combined with 5-androstenedione.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Ziconotide is combined with 5-methoxy-N,N-dimethyltryptamine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Evidence Level

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Skov MJ, Beck JC, de Kater AW, Shopp GM: Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class. Int J Toxicol. 2007 Sep-Oct;26(5):411-21. [PubMed:17963128]
  2. McIntosh M, Cruz LJ, Hunkapiller MW, Gray WR, Olivera BM: Isolation and structure of a peptide toxin from the marine snail Conus magus. Arch Biochem Biophys. 1982 Oct 1;218(1):329-34. [PubMed:7149738]
  3. Miljanich GP: Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem. 2004 Dec;11(23):3029-40. [PubMed:15578997]
  4. McGivern JG: Ziconotide: a review of its pharmacology and use in the treatment of pain. Neuropsychiatr Dis Treat. 2007 Feb;3(1):69-85. [PubMed:19300539]
External Links
KEGG Drug
D06363
PubChem Substance
347910345
ChEMBL
CHEMBL2103752
Wikipedia
Ziconotide
ATC Codes
N02BG08 — Ziconotide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentMalignancies / Pain NOS / Pain, Intractable / Pain, Neuropathic1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Malignancies / Pain NOS1
3CompletedTreatmentPain NOS2
4CompletedNot AvailablePeripheral Neuropathy1
4WithdrawnTreatmentPainful Myelopathy / Painful Neuropathy1
Not AvailableCompletedNot AvailablePatients With Severe Chronic Pain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, solutionIntrathecal100 ug/1mL
Injection, solutionIntrathecal100 μg/ml
Injection, solutionIntrathecal25 μg/ml
Injection, solutionIntrathecal25 ug/1mL
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5859186No1999-01-122011-12-30Us
US5364842No1994-11-152016-12-30Us
US8653033No2014-02-182024-10-01Us
US8765680No2014-07-012024-10-01Us
US9707270No2017-07-182024-10-01Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Drug created on March 19, 2008 10:21 / Updated on May 09, 2019 00:10